Atrial Fibrillation Management

Patient Selection for Catheter Ablation

• The European Society of Cardiology recommends catheter ablation as a first-line option for patients with paroxysmal atrial fibrillation, particularly in younger patients with symptomatic paroxysmal atrial fibrillation and patients with atrial fibrillation and heart failure with reduced ejection fraction (HFrEF) with high probability of tachycardia-induced cardiomyopathy 1
• Patients with left ventricular ejection fraction (LVEF) ≥25% show better outcomes than those with LVEF <25%, and catheter ablation in HFrEF patients with atrial fibrillation can significantly improve LVEF (+8.0% vs. +0.2% with medical therapy) 2
• The best candidates for AF ablation have favorable characteristics such as recent onset AF, recent onset HF, younger patients (<65 years), LVEF ≥25%, left atrial diameter <55mm, and symptomatic despite rate control 2

Anticoagulation Therapy

• The European Society of Cardiology recommends oral anticoagulation to be initiated at least 3 weeks prior to ablation, with uninterrupted oral anticoagulation during the procedure, and continuation of oral anticoagulation for at least 2 months post-procedure 1
• Long-term anticoagulation should be based on the patient's CHA2DS2-VASc score, regardless of perceived ablation success 1
• Continuation of oral anticoagulation during the procedure is recommended, with an INR close to 2.0 if using VKAs 3

Clinical Outcomes

• In the CASTLE-AF trial, ablation reduced the composite endpoint of death or heart failure hospitalization (28.5% vs. 44.6%) 2
• Ablation results in significant LVEF improvement (+8% to +11%) compared to rate control strategies, with success rates of 80-88% for maintaining sinus rhythm in heart failure patients and 90% success rates in paroxysmal AF cases 2, 4
• Long-term success rates range from 56-78% after a single procedure, with higher success (up to 78%) after multiple procedures if needed 4
• Major complications occur in approximately 6% of procedures, including pulmonary vein stenosis, thromboembolism, and cardiac perforation 4

Medical Therapy

• The European Heart Journal guidelines recommend amiodarone as a Class I-A recommendation for patients with HFrEF and atrial fibrillation, with a starting dose of 400-600 mg daily and maintenance dose of 100-200 mg daily 2, 5
• If amiodarone fails or is contraindicated, the guidelines suggest considering other Class III antiarrhythmic drugs (sotalol or dofetilide) with appropriate monitoring 2
• Guideline-directed medical therapy for HF includes RAAS inhibitors, beta-blockers, mineralocorticoid antagonists, and diuretics as appropriate, with first-line options including catheter ablation (Class IIa-B recommendation) and amiodarone (Class I-A recommendation) 2

Procedure and Follow-up

• Pulmonary vein isolation (PVI) should be the cornerstone technique for catheter ablation in paroxysmal AF cases, according to the European Heart Journal 3
• Early recurrences (within 6 weeks) should be managed with a "watch-and-wait" approach, as recommended by the European Heart Journal 3
• Late recurrences (>3 months) can be treated with cardioversion ± antiarrhythmic drugs, and repeat ablation should be considered in patients who benefited from the initial procedure 2
• Comorbidities such as hypertension, diabetes, and chronic kidney disease should be optimally controlled before ablation to improve outcomes 3
• An AF Heart Team approach is recommended for complex cases, especially for severe HFrEF, with a multidisciplinary team discussing treatment options 2